| INTRODUCTION
Over 202 million people worldwide were estimated to be living with peripheral artery disease (PAD) in 2010, with estimated prevalence rates of 9% in North America and 11% in Europe. 1 The spectrum of PAD includes acute and chronic limb ischemia, asymptomatic PAD, claudication, and critical limb ischemia. 2, 3 PAD is a strong predictor of myocardial infarction (MI), stroke, and death from vascular causes, 4, 5 with an annual incidence of approximately 5% for the composite endpoint of stroke, MI, and death in patients with PAD over 1 year. 6 Understanding the current trends in PAD prevalence and risk factors is critical in guiding preventive strategies to reduce the burden of PAD. However, contemporary, real-world data regarding patient profiles, treatment patterns, and cardiovascular (CV) risks for PAD patients beyond 1 year are insufficient, and are often limited to a single geographic region.
To address gaps in evidence for characterization of longer-term ischemic risk in PAD patients, we analyzed 4-year data from the REduction of Atherothrombosis for Continued Health (REACH) Registry, an international registry of atherothrombosis [7] [8] [9] in patients with symptomatic PAD with no history of stroke or transient ischemic attack (TIA), focusing on both systemic (MI, stroke, and CV death) and limb ischemic complications (lower limb amputation, peripheral bypass graft, and percutaneous intervention for PAD). Patients with prior stoke or TIA were excluded, because the risk and benefit balance of antithrombotic agents in this population is specific and has been previously published as a separate analysis. 10 The objectives of the present study were to (1) describe annual rates of systemic ischemic events (MI, stroke, and CV death) over 4 years globally and by geographic region, and to identify associated risk factors; and (2) to describe limb ischemic event rates (a composite of lower limb amputation, peripheral bypass graft, and percutaneous intervention for PAD) over 2 years.
| METHODS

| Population
The design, methods, and main results of the REACH Registry, an international, prospective, observational study, have been previously described. Data were collated centrally using standardized case report forms. The initial follow-up period was 2 years, but centers were invited to participate in a 2-year extension. Only patients with PAD and no history of stroke or TIA were included in the present analysis.
Signed informed consent was obtained from all patients, and the institutional review board in each country approved the protocol. 
| Outcomes
Following enrollment, detailed baseline characteristics, treatment, and outcomes were collected annually. Endpoints were not adjudicated and were based on physician report at the time of follow-up. We analyzed 3 systemic ischemic outcomes over 4 years: nonfatal MI, nonfatal stroke, and CV death; and 3 limb ischemic outcomes at 2 years: lower limb amputation, peripheral bypass graft, and percutaneous intervention for PAD. Limb ischemic outcomes were not adjudicated, but were tracked on a declarative basis at the end of followup. Consequently, due to missing data at 4 years, this endpoint was analyzed at 2 years.
The primary outcome was the composite of the 3 systemic ischemic events, and the secondary outcome was the composite of the 3 limb ischemic events. Other secondary outcomes of interest included CV death, MI, and stroke analyzed separately, as well as CV hospitalization.
Stroke was verified by a neurologist consultation or hospital records. CV death was defined as any MI or stroke followed by death in the next 28 days regardless of the cause, death from pulmonary embolism, heart failure, death following vascular surgery, death following a visceral or limb infarction, or any sudden death unless proven to be non-CV by autopsy.
| Statistical analysis
Descriptive statistics, including frequencies and percentages for categorical variables, and mean and standard deviation for continuous variables were calculated to describe the patients' baseline characteristics, medical history, and treatment patterns using the overall study population. Kaplan-Meier estimates were used to assess cumulative incidence rates at each year of follow-up. Patients from each region were also investigated as subgroups.
The exact date of each systemic ischemic event was systematically collected, whereas limb events were collected on a yearly basis during follow-up visits, precluding assignment of a precise date.
Therefore, systemic and limb ischemic outcomes were analyzed separately. 
| Baseline characteristics
In the overall population, the mean age was 70 AE 10 years, and 69.2% were men. At enrollment, 47.3% had diabetes mellitus, 66.2%
had hypercholesterolemia, 89.1% had hypertension, 20.9% were current smokers, and 18.7% were overweight/obese. Important differences in baseline characteristics were observed according to geographic region (Table 1) .
| Systemic ischemic events
The 2-year rate of systemic ischemic events (CV death, MI, or stroke)
in the overall population was 9.1%, and the 4-year rate was 17.6%
( Figure 1 ). The rate of systemic ischemic events increased cumulatively by approximately 4% to 5% for each year of follow-up ( Figure 1 ). The primary outcome was mainly driven by CV death, accounting for half of the composite outcome, with an increase of 3% each year (2.7%, 5.2%, 8.2%, 11.1%) ( Figure 2A ). Nonfatal MI increased from 1.3% to 2.4% to 3.3% to 4.4% ( Figure 2B ) with each additional year of follow-up, and nonfatal stroke from 1.0% to 2.3% to 3.3 to 4.5% ( Figure 2C) . Similarly, the rate of CV hospitalization increased cumulatively over the 4 years of follow-up from 17.8% the first year to 26.3% to 33.4% and 38.3% the fourth year ( Figure 2D ). 
| According to geographic region
| Risk factors associated with systemic ischemic events
Renal impairment (HR = 2.98, 95% CI: 1.69-3.12, P < 0.01), heart fail- 
| Limb ischemic events
The 2-year rate of the composite endpoint of limb ischemic events was 5.7%. Angioplasty and/or stenting for PAD accounted for 3.2% of these events, peripheral bypass graft accounted for 2.1%, and lower limb amputation accounted for 1.3% (patients could experience more than 1 event, explaining why the total was lower than the sum of each event). Overall, the composite outcome of systemic and limb ischemic events was 11.9% at 2 years.
| DISCUSSION
This contemporary and geographically diverse study of patients with symptomatic PAD in routine clinical practice confirmed that the ischemic event rate remains high, with a cumulative 4-year systemic event risk of 17.6%, mainly driven by CV mortality. The rate increased over follow-up (~4%-5% per year), and there were no major differences observed across the geographic regions except for Japan, where patients experienced a lower rate of ischemic events over time. PAD patients also experienced relatively high rates of severe limb ischemic events (approximately 6% at 2 years, including a 1.3% rate of major amputations). Independent risk factors associated with the increased systemic ischemic event rate were renal impairment, heart failure, single or poly vascular disease, a history of MI, a history of diabetes, and older age. Statin use was the only factor associated with a decreased risk of recurrent ischemic events over 4 years.
The factors associated with increased ischemic events observed in this analysis were consistent with the usual CV risk factors for atherosclerotic disease. 2, 13, 14 A previous analysis of the REACH Registry 9 and other studies [15] [16] [17] [18] suggested that patients with PAD do not achieve CV risk factor control as frequently as patients with other established atherothrombotic diseases, such as cerebrovascular disease or CV disease. In the REACH Registry, PAD patients with 3 to 5 controlled risk factors had fewer major CV events (ie, MI, stroke, CV death) compared with PAD patients with poor control (0-2 risk factors controlled, 2.66% vs. 3.52% 1-year rates, P = 0.17). 19, 20 In the present analysis, use of statin therapy was associated with reduced risk of ischemic events. European and US guidelines recommend low-density lipoprotein (LDL) cholesterol reduction in patients at high CV risk. 21, 22 A previous analysis of the REACH Registry showed a reduction of adverse limb outcomes in patients treated with statins for symptomatic PAD as well as overall ischemic events. 23 The addition of more potent treatment regimens and more aggressive reduction of LDL cholesterol could provide even greater be assessed in the specific population of PAD patients.
Residual ischemic risk was uniformly distributed over the different geographic areas, except for Japan, where patients experienced lower event rates. The explanations for such differences have been described previously. 29 Briefly, differences in disease management and medication use have been reported (in particular, the use of clopidogrel is substantially higher in Japan than in other regions of the world), which may have contributed to some extent in the improved outcomes in Japan, supported by evidence that clopidogrel use may be superior to aspirin in reducing major CV events in PAD FIGURE 1 Cumulative incidence rates of primary outcome of CV death, MI, or stroke for post-MI patients with no history of TIA/stroke. Abbreviations: CV, cardiovascular; MI, myocardial infarction; TIA, transient ischemic attack
Cumulative incidence rates of cardiovascular outcomes in PAD patients with no history of stroke or TIA by year of follow-up. Abbreviations: MI, myocardial infarction; PAD, peripheral artery disease; TIA, transient ischemic attack patients. 30, 31 In addition, gaps in country-based payer policies and healthcare systems might explain differences in risk factor prevalence and management. Moreover, genetic susceptibilities and lifestyle differences may also play a role in risk variation. 29 Nevertheless, residual risk remains high, and events accrued progressively over time across all geographic areas.
Antiplatelet agents are a cornerstone of the treatment of atherothrombotic disease. Patients with previous stroke or TIA were excluded from the present analysis, as they present a specific risk-tobenefit balance of antithrombotic use. 10 However, antiplatelet agents
were not associated with a statistically significant reduction in risk of Ischemic Stabilization, Management, and Avoidance) trial in a subgroup of patients diagnosed with PAD showed a trend for a benefit of clopidogrel plus aspirin over aspirin alone in this population, with a reduction in MI rates. 19, 34 At the time the REACH Registry was established, the novel oral antithrombotic agents prasugrel, ticagrelor, vorapaxar, or rivaroxaban were not available. Therefore, the present analysis cannot provide insights on the benefit of those agents.
Results of the EUCLID (Examining Use of tiCagreLor In paD) trial, which compared monotherapy with ticagrelor or clopidogrel in PAD patients without indication for dual antiplatelet therapy, did not show a reduction in composite ischemic or limb events or in major bleeding, although a reduction in ischemic stroke was observed. 35 Of note, patients who were homozygous for loss of function alleles to clopidogrel were excluded, though this exclusion did not seem to be the Therefore, all patients included in the EUCLID trial were receiving effective antiplatelet therapy. 35 The use of a dual antiplatelet therapy rather than a single antiplatelet therapy might provide additional benefit for PAD patients.
A subgroup analysis of the PLATO (Study of PLATelet inhibition and patient Outcomes) trial showed that the benefit of ticagrelor over clopidogrel in acute coronary syndrome patients was consistent in the subgroup of PAD patients compared with the global population. 36 A similar analysis from the post-MI PEGASUS (PEGASUS-TIMI 54) trial also showed a consistent benefit of ticagrelor over placebo in addition to aspirin in post-MI patients with PAD. 37, 38 Similarly, a recent analysis from the DAPT (The Dual Antiplatelet Therapy Study) trial showed clear benefit of prolonged dual antiplatelet therapy in PAD patients treated with coronary stents. There are some limitations to the present analysis. The collection of limb events and systemic events was not done in the exact same method, and there was no assignment of a precise date for limb events. Additionally, limb events were tracked on a declarative basis at the end of follow-up, leading to some missing data at the 4-year time point. Consequently, our analysis was underpowered to determine risk factors for these occurrences. These analyses are drawn from an observational registry; the results presented here are therefore descriptive, and analyses on the determinants of residual risk as well as analyses on geographic differences must be interpreted cautiously. Clinical events were not adjudicated in the REACH Registry, but measures were taken to select high-quality physicians, and diagnoses were provided by hospitals and doctors based on their expertise. Patient adherence to medication was not captured in the registry, and adherence could impact patient outcomes. Finally, although the data were taken from a large cohort, the analysis may have been underpowered for some comparisons. 
| CONCLUSION
